Welcome to our dedicated page for Akili news (Ticker: AKLI), a resource for investors and traders seeking the latest updates and insights on Akili stock.
Akili Interactive Labs (AKLI) is a leader in developing prescription-grade digital therapeutics that combine neuroscience with advanced technology to address cognitive impairments. This page serves as the definitive source for verified news and official updates directly impacting Akili's position in the digital health sector.
Investors and healthcare professionals will find timely updates on clinical trial results, regulatory clearances, strategic partnerships, and product innovations. Our curated collection includes earnings reports, research collaborations, and technology deployment milestones—all essential for understanding Akili's evidence-based approach to cognitive health solutions.
Key areas covered include FDA authorization progress, peer-reviewed study outcomes, licensing agreements with healthcare providers, and advancements in neuroadaptive software platforms. Each update is vetted for relevance to Akili's mission of transforming patient care through clinically validated digital interventions.
Bookmark this page for streamlined access to AKLI's evolving story in digital medicine. Check back regularly for objective reporting on how Akili continues to shape the future of neurotechnology and therapeutic software development.
Akili, Inc. (NASDAQ: AKLI) will conduct a conference call and webcast to discuss its financial and operational results for Q1 2023 on May 11, 2023, at 4:30 p.m. ET. The event will be accessible via www.akiliinteractive.com under the Investor Relations section. Investors can join by calling 888-575-5163 (toll-free) or 416-764-8620 (international), referencing “Akili Q1 2023 Earnings.” Akili is at the forefront of digital medicine, focusing on innovative cognitive treatments through engaging video game experiences, validated by clinical trials. Their unique platform aims to address cognitive impairments with enhanced user experiences.
Akili, Inc. (AKLI) reported significant growth in EndeavorRx prescriptions, with a 37% increase in Q4 2022 over Q3 2022 and a 166% increase in FY 2022 over FY 2021. The company plans to expand its sales force and pursue an FDA label expansion for older children with ADHD. Financial highlights show a net loss of $8.0 million for FY 2022, a reduction compared to the previous year, while total revenues decreased to $323,000. Akili reaffirms non-GAAP operating expenses for FY 2023 at $55M - $60M and expects a cash runway into Q1 2025, bolstered by a cash position of $136.1 million as of Dec 31, 2022.
Akili, Inc. (Nasdaq: AKLI) announced a conference call and webcast to discuss its Q4 2022 and full year 2022 financial results on March 7, 2023, at 4:30 p.m. ET. Investors can access the live audio on the company's website. Akili is focused on developing cognitive treatments through digital technologies that engage users via video game experiences, targeting cognitive impairment.
Akili, Inc. (Nasdaq: AKLI), a pioneer in digital medicine, will participate in the Cowen 43rd Annual Health Care Conference in Boston on March 8. Highlights include a panel discussion with Scott Kollins, Chief Medical Officer, at 8 AM on prescription digital therapeutics and a 9:50 AM fireside chat featuring Co-Founder and CEO Eddie Martucci along with President Matt Franklin. The company will engage with investors throughout the day. Akili is noted for its innovative treatments targeting cognitive impairments through engaging video game experiences, supported by rigorous clinical research.
FAQ
What is the current stock price of Akili (AKLI)?
What is the market cap of Akili (AKLI)?
